Výsledky vyhledávání - "Fosbretabulin Tromethamine"

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Autor: Robert L. Coleman, Lainie P. Martin, Jeanne M. Schilder, Bradley J. Monk, Gregory P. Sutton, Krishnansu S. Tewari, Jai Balkissoon, Joan L. Walker, Carol Aghajanian, Michael W. Sill, Christopher J. Darus

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(19)

Purpose The vascular disrupting agent fosbretabulin tromethamine selectively targets pre-existing tumor vasculature, which causes vascular shutdown and leads to cancer cell death and necrosis. Antiangiogenesis agents such as bevacizumab, a humanized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7d50a081278f4d665e05c703d0b8c3d
https://pubmed.ncbi.nlm.nih.gov/27217446

Zobrazit plný text záznamu

Fosbretabulin for the treatment of anaplastic thyroid cancer

Autor: Laura D. Locati, Roberta Granata, Lisa Licitra

Publikováno v: Future oncology (London, England). 10(13)

ABSTRACT Fosbretabulin tromethamine is a vascular disrupting agent, which is a type of drug that is designed to damage the vasculature (blood vessels) of cancer tumors, causing central necrosis. This drug showed activity against anaplastic thyroid ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da9663a47348ca955979f71af7f88d77
https://pubmed.ncbi.nlm.nih.gov/25396774

Zobrazit plný text záznamu

A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial

Autor: Jeffrey D. Neidhart, Edward B. Garon, Nashat Y. Gabrail, S. P. Lu, J. A. Neidhart, Moacyr Ribeiro de Oliveira, J. Balkissoon, Fairooz F. Kabbinavar

Publikováno v: Journal of Clinical Oncology. 29:7559-7559

7559 Background: Inhibition of angiogenesis has clinical benefits in NSCLC. Depriving tumors of blood flow by adding bevacizumab (B) to other vasculature-directed agents has been hampered by toxici...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3aa1e5b2ed2c60931b0be04ab2105cb8
https://doi.org/10.1200/jco.2011.29.15_suppl.7559

Zobrazit plný text záznamu

A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial

Autor: Charles Lu, S. Lu, Shanthi Marur, S. M. Karandikar, R. Ben-Yosef, Lisa Licitra, Scot C. Remick, J. Balkissoon, H. Koussis, Barbara J. Gitlitz, Ann Wild Gramza, Fadlo R. Khuri, Barbara Jarzab, Frank G. Ondrey, Rossella Elisei, Julie Ann Sosa, Bryan R. Haugen, Chandrasekhar Bal

Publikováno v: Journal of Clinical Oncology. 29:5502-5502

5502 Background: CA4P, a vascular disrupting agent (VDA), has shown clinical activity as monotherapy in patients with ATC. Results include a durable CR in a phase I trial and a median survival of 4.7 months with 34% of patients alive at 6 months and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::134783eb61c029051d1b5ced946d0d6c
https://doi.org/10.1200/jco.2011.29.15_suppl.5502

Zobrazit plný text záznamu

467 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial

Autor: J.D. Neidhart, Nashat Y. Gabrail, Jeffrey D. Neidhart, S. P. Lu, Fairooz F. Kabbinavar, Jai Balkissoon, M. Ribeiro de Oliveira, Edward B. Garon

Publikováno v: European Journal of Cancer Supplements. 8:150

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea3d09904035f2ab9d2c8a79756cf17d
https://doi.org/10.1016/s1359-6349(10)72174-1

Zobrazit plný text záznamu

Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial

Autor: Nashat Y. Gabrail, Jeffrey D. Neidhart, Edward B. Garon, J. Balkissoon, Fairooz F. Kabbinavar, S. P. Lu, Moacyr Ribeiro de Oliveira, J. A. Neidhart

Publikováno v: Journal of Clinical Oncology. 28:7587-7587

7587 Background: CA4P is a small-molecule tumor vascular disrupting agent (VDA) that has shown additive effects in combination with chemotherapy and antiangiogenic therapy. This phase II study eval...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f935ecba83ea570e32ecb5e63261d8d
https://doi.org/10.1200/jco.2010.28.15_suppl.7587

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání